Clinical trial
Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
NCT00411151 · Johannes Gutenberg University Mainz, Other · Completed
Key facts
| NCT number | NCT00411151 |
|---|---|
| Title | Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer |
| Official title | An Open-label, Multicenter Phase II Trial of Sunitinib for Patients With Chemo-refractory Metastatic Gastric Cancer |
| Lead sponsor | Johannes Gutenberg University Mainz, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Adenocarcinoma, Barrett Esophagus |
| Intervention type | Drug |
| Interventions | Sunitinib-Malate |
| Enrollment | 52 |
| Start date | Dec 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Dec 13, 2006 |
| Last update posted | Jan 20, 2011 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: